Article
|
|
|
Services
|
|
|
Google Scholar
|
|
|
PubMed
|
|
|
|
REPLY
Control of Vancomycin-Resistant Enterococcus
Robert A. Weinstein, MD;
Mary Hayden, MD; and
Sarah Slaughter, MD
15 June 1997 | Volume 126 Issue 12 | Page 1001
IN RESPONSE:
We agree with Dr. Lai's restatement of our findings. In addition, Dr. Lai asks specifically about the cost-effectiveness of rectal surveillance cultures in an intensive care unit in which vancomycin-resistant enterococci are already endemic.
Most patients who are colonized by vancomycin-resistant enterococci never develop infections, and those who do also have multiple comorbid conditions that complicate the assessment of treatment costs. Moreover, the incremental benefit of surveillance cultures, beyond that of other control measures, is difficult to measure. Therefore, the cost-effectiveness of rectal surveillance cultures might be difficult to ascertain, even in the context of a prospective, controlled clinical trial. We have found that surveillance cultures are most helpful in tracking responses to an intervention and that they allow epidemiologic typing of isolates. If isolates are found to represent a single strain, evaluation for a possible common source of contamination should be done. In most instances, however, dissemination of a single strain of vancomycin-resistant enterococci results from lapses of hygiene that result in indirect patient-to-patient spread of organisms via the unwashed hands of health care workers and environmental contamination. The presence of a single strain suggests that maximal control efforts [1] may be effective. Outbreaks of multiple strains of vancomycin-resistant enterococci seem to be more difficult to control; this may reflect the repeated introduction of resistant strains from other units, other hospitals, or nursing homes [2] or the presence of a promiscuous resistance plasmid. If typing of surveillance isolates indicates that multiple strains are circulating, additional control strategies may include developing a source-patient profile; evaluating newly admitted patients as possible sources; introducing more stringent antibiotic controls; developing a vancomycin-resistant enterococci cohort system; and using more aggressive standard precautions, as described below.
With regard to Dr. Lai's second question, we note that the durability of colonization with vancomycin-resistant enterococci may depend on patients' comorbid conditions and antibiotic exposures. In our intensive care unit [3], as in Dr. Lai's [4], patients seem to remain colonized during their entire stay. For this reason and because patients may introduce enterococci from other units or other institutions, we recommend that gloves and handwashing be used for contact with all acutely ill patients and their environments in hospitals in which vancomycin-resistant enterococci are endemic. This approach goes beyond standard precautions [5] to include the intact skin and the patient's environment.
|
Author and Article Information
|
|---|
Cook County Hospital and Rush Medical College, Chicago, IL 60612
Providence Hospital, Portland, OR 97213
1. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol. 1995; 16:105-13.
2. Elizaga ML, Beezhold D, Hayden MK, Rice T, Nathan C, Buccelli C, et al. The prevalence of colonization with vancomycin-resistant enterococci (VRE) among hospitalized residents of long-term care facilities (LTCF) [Abstract]. In: Program of the 34th Annual Meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, LA: 352.
3. Bonten MJ, Hayden MK, Nathan C, Van Voorhis J, Matushek M, Slaughter S, et al. The epidemiology of patient colonization and environmental contamination with vancomycin-resistant enterococci: the challenge for infection control. Lancet. 1996; 348:1615-9.
4. Lai KK, Fontecchio S, Kelley AL, Melvin ZS. When is it safe to take patients colonized with vancomycin-resistant Enterococcus faecium (VREF) off isolation? [Abstract] In: Program of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco, CA:J36.
5. Garner JS. Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996; 17:53-80.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Article
|
|
|
Services
|
|
|
Google Scholar
|
|
|
PubMed
|
|
|
|